Showing results (251-260 of 303) with videos related to
Sort By:
Pageof 31
Research Square|October 7, 2024
Antibody responses against influenza A decline with successive years of annual influenza vaccination: results from an Australian Healthcare Worker cohortSheena Sullivan, Arseniy Khvorov, Louise Carolan, et al.The Journal of Infection|February 20, 2025
The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth doseNadia Mazarakis, Zheng Quan Toh, Eleanor Neal, et al.Journal of Virology|February 16, 2018
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph NodesSinthujan Jegaskanda, Rosemarie D Mason, Sarah F Andrews, et al.Nature Medicine|July 15, 2020
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19Jennifer A Juno, Hyon-Xhi Tan, Wen Shi Lee, et al.ACS Nano|June 27, 2022
Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA VaccineYi Ju, Wen Shi Lee, Emily H Pilkington, et al.The New England Journal of Medicine|June 23, 2021
SARS-CoV-2 Variants and VaccinesPhilip R Krause, Thomas R Fleming, Ira M Longini, et al.The Journal of Infectious Diseases|February 25, 2016
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody ResponseAnna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, et al.The Journal of Infectious Diseases|March 25, 2015
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive AdultsBeth D Kirkpatrick, Anna P Durbin, Kristen K Pierce, et al.JCI Insight|July 12, 2021
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assayEster Lopez, Ebene R Haycroft, Amy Adair, et al.Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.Pageof 31